What did @ali_clifton actually say?
She's five weeks and one day into what appears to be a testosterone or hormone therapy protocol and feeling nothing. No sore breasts, no nausea, no recognizable sign that anything is happening. She's frustrated, a little scared, and half-predicting she'll "come back and slap" herself when symptoms hit hard around week seven. That's the core of it: she's waiting for her body to signal that treatment is working, and the silence is unnerving.
She's also framing the experience for others on the same journey, which is worth noting. This isn't medical advice. It's a relatable window into the psychological weight of the symptom-watching phase, a phase that's genuinely underrepresented in clinical conversations about hormone therapy timelines.
Does the science back this up?
Yes, largely. The timeline she's describing is consistent with what pharmacokinetic research actually shows about testosterone therapy onset. Many patients report a lag between starting treatment and experiencing noticeable physiological or symptomatic changes, and that lag is not a sign of failure.
A 2014 review by Bhasin et al. in the Journal of Clinical Endocrinology and Metabolism documented that testosterone's effects on different tissues follow distinct timelines. Mood and energy changes may begin within weeks, but other effects, including changes to breast tissue sensitivity, libido, and body composition, can take two to three months to become apparent. The "week seven" prediction she makes is not arbitrary. Many providers and patients report a noticeable shift somewhere in weeks six through ten. A 2020 study by Glintborg and colleagues in the European Journal of Endocrinology similarly found that patient-reported outcomes often lag behind measurable serum changes by several weeks.
What did they get wrong (or right)?
She got the emotional reality right. The symptom-watching phase is genuinely stressful, and the tendency to scan your body for proof that something is working is well documented in adherence literature. Researchers like Horne et al. (2013, Psychology and Health) have shown that patients who don't feel immediate effects are at higher risk of discontinuing treatment prematurely, which makes her public acknowledgment of this feeling actually useful content.
What she got slightly wrong, or at least imprecise, is the implication that nausea and breast tenderness are expected or desired markers of hormone therapy working. Those symptoms are more associated with estrogen fluctuation, not testosterone optimization. If she's on a testosterone protocol, breast tenderness could signal aromatization, meaning testosterone converting to estradiol at a rate that warrants monitoring, not celebration. That's a clinical nuance worth flagging. Chasing those symptoms as proof of efficacy could lead someone to misread a side effect as a green light.
What should you actually know?
If you're in the symptom-waiting phase on a hormone protocol, the absence of dramatic early symptoms is not evidence that your treatment isn't working. Serum testosterone levels and downstream hormonal cascades take time to stabilize. Most clinical guidelines, including those from the Endocrine Society, suggest evaluating response at three to six months, not five weeks.
Breast tenderness specifically is worth mentioning to your provider, not because it confirms efficacy, but because it can indicate elevated estradiol levels that may need management. A 2019 paper by Traish et al. in the Journal of Clinical Medicine outlined how aromatase activity varies significantly between patients and affects both symptom profiles and therapeutic outcomes.
- Symptom onset timelines vary widely between individuals and delivery methods.
- Absence of side effects at five weeks is not a failure signal.
- Breast tenderness on testosterone therapy warrants a conversation with your provider, not reassurance.
- Early scan results and lab work are more reliable indicators than symptoms alone.
Bottom line
She's not spreading misinformation. She's sharing a human experience that a lot of people on hormone protocols go through and rarely talk about openly. The five-to-seven week window she describes as a turning point is consistent with clinical timelines. The one thing worth pushing back on is framing breast tenderness as a desired confirmation. On a testosterone protocol, that symptom has a specific clinical meaning that deserves attention, not wishful thinking. Go into your week-six scan with lab orders, not just hope.